What is claimed:

1. A method for the treatment of bone disease in a patient suffering from such disorder comprising administering to said patient an effective amount of a composition having the formula:

$$\begin{array}{c|c}
R_{5} & X & A_{1} \\
R_{7} & N & N
\end{array}$$

wherein

5

10

20

25

30

Ar is a substituted or unsubstituted mono- or bi-cyclic aryl or heteroaryl ring system of about 5 to about 12 atoms and where each monocyclic ring may contain 0 to about 3 hetero atoms, and each bicyclic ring may contain 0 to about 4 hetero atoms selected from N, O, and S provided said hetero atoms are not vicinal oxygen and/or sulfur atoms and where the substituents may be located at any appropriate position of the ring system and are described by R;

X is a bond, O, S, SO, SO₂, OCH₂, C=C, C=C, C=S, SCH₂, NH, NHCH₂, NR₄, or NR₄CH₂;

R independently includes hydrogen, alkyl, phenyl, aralkyl, aralkenyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, aralkoxy, aryloxy, acyloxy, halo, haloalkyl, nitro, cyano, amino, mono- and di-alkylamino, acylamino, carboxy, carboxyalkyl, carbalkoxy, carbaralkoxy, carbalkoxyalkyl, carbalkoxyalkenyl, aminoalkoxy, amido, mono- and di-alkylamido, and N,N-cycloalkylamido, sulfonyl, mono- and di-alkyl sulfamoyl, mono- and di-alkyl sulfamoyl, halophenyl, or benzoyl, and R and R together may also form a ketone group;

R₄ is alkyl, -CH2-CH2- or -CH2-CH2-; and

R5, R6, and R7 are independently hydrogen, alkyl, alkylthio, cycloalkyl, hydroxy, alkoxy, aralkoxy, aryl, halo, haloalkyl, carboxy or carbalkoxy; or

a pharmaceutically acceptable salt thereof.

2. A method for the treatment of inflammation in a patient suffering from such disorder comprising administering to said patient an effective amount of a composition having the formula:

$$\begin{array}{c|c}
R_5 & X & A_1 \\
R_7 & N & N
\end{array}$$

wherein

5

10

Ar is a substituted or unsubstituted mono- or bi-cyclic aryl or heteroaryl ring system of about 5 to about 12 atoms and where each monocyclic ring may contain 0 to about 3 hetero atoms, and each bicyclic ring may contain 0 to about 4 hetero atoms selected from N, O, and S provided said hetero atoms are not vicinal oxygen and/or sulfur atoms and where the substituents may be located at any appropriate position of the ring system and are described by R;

X is a bond, O, S, SO, SO₂, OCH₂, C=C, C≡C, C=S, SCH₂, NH, NHCH₂, NR₄, or NR₄CH₂;

15

R independently includes hydrogen, alkyl, phenyl, aralkyl, aralkenyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, aralkoxy, aryloxy, acyloxy, halo, haloalkyl, nitro, cyano, amino, mono- and di-alkylamino, acylamino, carboxy, carboxyalkyl, carbalkoxy, carbaralkoxy, carbalkoxyalkyl, carbalkoxyalkenyl, aminoalkoxy, amido, mono- and di-alkylamido, and N,N-cycloalkylamido, sulfonyl, mono- and di-alkyl sulfamoyl, sulfamoyl, mono- and di-alkyl sulfamoyl, halophenyl, or benzoyl, and R and R together may also form a ketone group;

R₄ is alkyl, -CH2-CH2- or -CH2-CH2-; and

25

20

R5, R6, and R7 are independently hydrogen, alkyl, alkylthio, cycloalkyl, hydroxy, alkoxy, aralkoxy, aryl, halo, haloalkyl, carboxy or carbalkoxy; or

a pharmaceutically acceptable salt thereof.

30

3. A method of inhibiting cell proliferation, differentiation, or mediator release in a patient suffering from a disorder characterized by such proliferation and/or differentiation and/or mediator release comprising administering to a patient a composition selected from:

- 4-(naphthalen-2-ylethynyl)-6,7-dimethoxyquinazoline,
- 4-(4-hydroxyphenyl)-6,7-dimethoxyquinazoline hydrochloride
- 4-phenylacetylenyl-6,7-dimethoxyquinazoline,
- 4-(2-phenylphenyl)-6,7-dimethoxyquinazoline,
- 5 4-(1-methylindol-3-yl)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(4-phenylpiperidin-1-yl)-6,7-dimethoxyquinazoline,
 - 4-[4-(3-chlorophenyl)piperazin-1-yl]-6,7-dimethoxyquinazoline,
 - (±)-4-(2-methyl-1,2,3,4-tetrahydroguinolin-1-yl)-6,7-dimethoxyguinazoline hydrochloride,
 - 4-(1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline hydrochloride,
- 10 4-(N-methyl-4-methoxyanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-4-chloro-anilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(2,3-dihydroindol-1-yl)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-3-trifluoromethylanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-3-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride,
- 15 4-(N-methyl-3-chloroanilino)quinazoline hydrochloride and
 - 4-(naphthalen-1-ylethynyl)-6,7-dimethoxyguinazoline; or
 - a pharmaceutically acceptable salt thereof.
- 20 4. The method of Claim 3 where said composition administered is selected from:
 - 4-(indazol-5-ylamino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methylanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-benzylanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methylanilino)-6-chloroquinazoline,
- 25 4-(N-ethyl-3-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-4-methylanilino)-6,7-dimethoxyguinazoline hydrochloride,
 - 4-(N-benzylamino)-6,7-dimethoxyquinazoline,
 - 4-(4-methoxybenzylamino)-6,7-dimethoxyquinazoline,
 - 4-(3,5-dimethoxybenzylamino)-6,7-dimethoxyquinazoline hydrochloride,
- 30 4-(N-methylanilino)quinazolin-4-yl) hydrochloride,
 - 4-(4-morpholin-4-ylanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(3-methoxythiophenoxy)-6,7-dimethoxyguinazoline,
 - 4-[N-(5-indanyl)amino]-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(3-chlorothiophenoxy)-6,7-dimethoxyquinazoline,
- 35 4-(3-aminopyrazolyl)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(1,4-benzodioxan-6-ylamino)-6,7-dimethoxyquinazoline hydrochloride,
 - $4-(\alpha-naphthylamino)-6,7-dimethoxyquinazoline hydrochloride,$
 - 4-(β-naphthylamino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(cyclohexylanilino)-6,7-dimethoxyquinazoline,
- 40 4-(N-methylanilino)-6,7-dimethoxyguinazoline hydrochloride, and

- 4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline; or a pharmaceutically acceptable salt thereof.
- 5 5. A pharmaceutical composition for effectively inhibiting CSF-1R tyrosine kinase activity by exhibiting inhibition of cell proliferation and/or differentiation and/or mediator release comprising a CSF-1R receptor inhibiting effective amount of a compound selected from:
- 10 4-(naphthalen-2-ylethynyl)-6,7-dimethoxyquinazoline,
 - 4-(4-hydroxyphenyl)-6,7-dimethoxyquinazoline hydrochloride
 - 4-phenylacetylenyl-6,7-dimethoxyquinazoline,
 - 4-(2-phenylphenyl)-6,7-dimethoxyquinazoline,
 - 4-(1-methylindol-3-yl)-6,7-dimethoxyquinazoline hydrochloride,
- 4-(4-phenylpiperidin-1-yl)-6,7-dimethoxyquinazoline,
 - 4-[4-(3-chlorophenyl)piperazin-1-yl]-6,7-dimethoxyquinazoline,
 - (±)-4-(2-methyl-1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-4-methoxyanilino)-6,7-dimethoxyquinazoline hydrochloride,
- 4-(N-methyl-4-chloro-anilino)-6,7-dimethoxyguinazoline hydrochloride,
 - 4-(2,3-dihydroindol-1-yl)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-3-trifluoromethylanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-3-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-3-chloroanilino)quinazoline hydrochloride and
- 4-(naphthalen-1-ylethynyl)-6,7-dimethoxyquinazoline; or a pharmaceutically acceptable salt thereof.
 - 6. The pharmaceutical composition of Claim 5 where said composition is selected
- 30 from:
 - 4-(indazol-5-ylamino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methylanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-benzylanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methylanilino)-6-chloroguinazoline,
- 35 4-(N-ethyl-3-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-4-methylanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-benzylamino)-6,7-dimethoxyquinazoline,
 - 4-(4-methoxybenzylamino)-6,7-dimethoxyguinazoline,
 - 4-(3,5-dimethoxybenzylamino)-6,7-dimethoxyquinazoline hydrochloride,
- 40 4-(N-methylanilino)quinazolin-4-yl) hydrochloride,

- 4-(4-morpholin-4-ylanilino)-6,7-dimethoxyquinazoline hydrochloride,
- 4-(3-methoxythiophenoxy)-6,7-dimethoxyquinazoline,
- 4-[N-(5-indanyl)amino]-6,7-dimethoxyquinazoline hydrochloride,
- 4-(3-chlorothiophenoxy)-6,7-dimethoxyquinazoline,
- 4-(3-aminopyrazolyl)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(1,4-benzodioxan-6-ylamino)-6,7-dimethoxyquinazoline hydrochloride,
 - $4-(\alpha-naphthylamino)-6,7-dimethoxyquinazoline hydrochloride,$
 - 4-(β-naphthylamino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(cyclohexylanilino)-6,7-dimethoxyquinazoline,
- 10 4-(N-methylanilino)-6,7-dimethoxyquinazoline hydrochloride, and
 - 4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline; or
 - a pharmaceutically acceptable salt thereof.

15 7. A compound selected from:

- 4-(indazol-5-ylamino)-6,7-dimethoxyquinazoline hydrochloride,
- 4-(N-methylanilino)-6,7-dimethoxyquinazoline hydrochloride,
- 4-(N-benzylanilino)-6,7-dimethoxyquinazoline hydrochloride,
- 20 4-(N-methylanilino)-6-chloroquinazoline.
 - 4-(N-ethyl-3-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-4-methylanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-benzylamino)-6,7-dimethoxyquinazoline,
 - 4-(4-methoxybenzylamino)-6,7-dimethoxyquinazoline,
- 4-(3,5-dimethoxybenzylamino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methylanilino)quinazolin-4-yl) hydrochloride.
 - 4-(4-morpholin-4-ylanilino)-6,7-dimethoxyguinazoline hydrochloride.
 - 4-(3-methoxythiophenoxy)-6,7-dimethoxyquinazoline,
 - 4-[N-(5-indanyl)amino]-6,7-dimethoxyquinazoline hydrochloride,
- 30 4-(3-chlorothiophenoxy)-6,7-dimethoxyquinazoline,
 - 4-(3-aminopyrazolyl)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(3,6-dioxananilino)-6,7-dimethoxyquinazoline hydrochloride,
 - $4-(\alpha-naphthylamino)-6,7-dimethoxyquinazoline hydrochloride,$
 - 4-(β-naphthylamino)-6,7-dimethoxyquinazoline hydrochloride,
- 35 4-(cyclohexylanilino)-6,7-dimethoxyquinazoline,
 - 4-(N-methylanilino)-6,7-dimethoxyquinazoline hydrochloride, and
 - 4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline; or
 - a pharmaceutically acceptable salt thereof.

8. A compound selected from:

- 4-(naphthalen-2-ylethynyl)-6,7-dimethoxyquinazoline,
- 5 4-(4-hydroxyphenyl)-6,7-dimethoxyquinazoline hydrochloride
 - 4-phenylacetylenyl-6,7-dimethoxyquinazoline,
 - 4-(2-phenylphenyl)-6,7-dimethoxyquinazoline,
 - 4-(1-methylindol-3-yl)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(4-phenylpiperidin-1-yl)-6,7-dimethoxyquinazoline,
- 10 4-[4-(3-chlorophenyl)piperazin-1-yl]-6,7-dimethoxyquinazoline,
 - (±)-4-(2-methyl-1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-4-methoxyanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-4-chloro-anilino)-6,7-dimethoxyquinazoline hydrochloride,
- 4-(2,3-dihydroindol-1-yl)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-3-trifluoromethylanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-3-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride,
 - 4-(N-methyl-3-chloroanilino)quinazoline hydrochloride and
 - 4-(naphthalen-1-ylethynyl)-6,7-dimethoxyquinazoline; or
- 20 a pharmaceutically acceptable salt thereof.